Document Detail


Topical ranibizumab as a treatment of corneal neovascularization.
MedLine Citation:
PMID:  23407316     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
PURPOSE: To examine the effect of topical ranibizumab on clinically stable corneal neovascularization (NV).
METHODS: This was a prospective, open-label, monocentric, uncontrolled noncomparative study. Ten eyes of 9 patients with corneal NV received topical ranibizumab (1%) 4 times a day for 3 weeks with a follow-up period of 16 weeks. The main corneal NV outcome measures were: neovascular area, the area occupied by the corneal neovessels; vessel caliber (VC), the mean diameter of the corneal neovessels; and invasion area (IA), the fraction of the total cornea area covered by the vessels. This study was conducted at the Massachusetts Eye and Ear Infirmary, Boston, MA.
RESULTS: Statistically significant decreases in neovascular area (55.3%, P < 0.001), which lasted through 16 weeks, and VC (59%, P < 0.001), which continued to improve up to week 16, were observed after treatment. No significant decrease was observed in IA (12.3%, P = 0.49). There was no statistically significant change in visual acuity or intraocular pressure. No adverse events ascribed to the treatment were noted.
CONCLUSIONS: Topical application of ranibizumab is effective in reducing the severity of corneal NV in the context of established corneal NV, mostly through decrease in VC rather than IA.
Authors:
Giulio Ferrari; Mohammad H Dastjerdi; Andre Okanobo; Sheng-Fu Cheng; Francisco Amparo; Nambi Nallasamy; Reza Dana
Related Documents :
23331376 - Zero delay switch technique in optical coherence tomography for duo enhanced vitreoreti...
24731756 - Should sleep laboratories have their own predictive formulas for continuous positive ai...
2435456 - Clinical aspects of herpetic eye diseases.
1933666 - Visual prognosis in central serous choroidopathy: residual amsler grid changes.
21088046 - Immune alterations after selective rapid eye movement or total sleep deprivation in hea...
6493716 - Timing of vitrectomy after penetrating ocular injuries.
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Cornea     Volume:  32     ISSN:  1536-4798     ISO Abbreviation:  Cornea     Publication Date:  2013 Jul 
Date Detail:
Created Date:  2013-06-10     Completed Date:  2014-01-08     Revised Date:  2014-07-02    
Medline Journal Info:
Nlm Unique ID:  8216186     Medline TA:  Cornea     Country:  United States    
Other Details:
Languages:  eng     Pagination:  992-7     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Topical
Adult
Aged
Angiogenesis Inhibitors / administration & dosage*
Antibodies, Monoclonal, Humanized / administration & dosage*
Blood Vessels / drug effects,  pathology
Cornea / blood supply
Corneal Neovascularization / drug therapy*,  physiopathology
Female
Humans
Intraocular Pressure / physiology
Male
Middle Aged
Ophthalmic Solutions
Prospective Studies
Treatment Outcome
Vascular Endothelial Growth Factor A / antagonists & inhibitors
Visual Acuity / physiology
Grant Support
ID/Acronym/Agency:
EY-019098/EY/NEI NIH HHS; K24 EY019098/EY/NEI NIH HHS
Chemical
Reg. No./Substance:
0/Angiogenesis Inhibitors; 0/Antibodies, Monoclonal, Humanized; 0/Ophthalmic Solutions; 0/VEGFA protein, human; 0/Vascular Endothelial Growth Factor A; 0/ranibizumab
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Azithromycin treatment increases survival of high-risk corneal allotransplants.
Next Document:  Handheld Slit Beam Techniques to Facilitate DMEK and DALK.